Form 8-K - Current report:
SEC Accession No. 0000950170-24-091220
Filing Date
2024-08-06
Accepted
2024-08-06 08:20:09
Documents
13
Period of Report
2024-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cogt-20240806.htm   iXBRL 8-K 56862
2 EX-99.1 cogt-ex99_1.htm EX-99.1 126624
3 GRAPHIC img214414700_0.jpg GRAPHIC 78289
  Complete submission text file 0000950170-24-091220.txt   422278

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cogt-20240806.xsd EX-101.SCH 28710
15 EXTRACTED XBRL INSTANCE DOCUMENT cogt-20240806_htm.xml XML 4697
Mailing Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451
Business Address 275 WYMAN STREET 3RD FLOOR WALTHAM MA 02451 617-945-5576
Cogent Biosciences, Inc. (Filer) CIK: 0001622229 (see all company filings)

EIN.: 465308248 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38443 | Film No.: 241177206
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)